Submission + - WHO ready to resume its trials of hydroxychloroquine (politico.com)
Meanwhile the Lancet has issued an “expression of concern” about the data and methodology of the study that suggested higher mortality rates for patients treated with hydroxychloroquine:
"we are issuing an Expression of Concern to alert readers to the fact that serious scientific questions have been brought to our attention".
Hydroxychloroquine made the headlines when U.S. President Trump publicly talked about its use against COVID-19.